SAN FRANCISCO - With Motif Bio plc's new drug application for iclaprim in acute bacterial skin and skin structure infections awaiting a February 2019 review at the FDA, the company leveraged IDWeek to unveil new wound care data from its pivotal trials highlighting a potential advantage in the realm of kidney safety.